HER 2 NEO Immunohistochemistry at Lahore PCR Lab

HER 2 NEO Immunohistochemistry at Lahore PCR Lab

The HER 2 NEO Immunohistochemistry (IHC) test is a specialized, highly sophisticated laboratory investigation performed on tissue biopsy specimens to evaluate the expression of the Human Epidermal Growth Factor Receptor 2 (HER2) protein. This protein, encoded by the ERBB2 proto-oncogene located on chromosome 17, is a transmembrane tyrosine kinase receptor involved in regulating cell growth, survival, and differentiation. When the HER2 gene is amplified or the protein is overexpressed, it leads to uncontrolled cellular proliferation and tumor progression. The HER 2 NEO Immunohistochemistry test at Lahore PCR Lab in Lahore, Pakistan, serves as a critical diagnostic, prognostic, and predictive tool, particularly for patients diagnosed with invasive breast carcinoma, gastric adenocarcinoma, and gastroesophageal junction cancers.

Immunohistochemistry works by utilizing highly specific, chemically labeled antibodies designed to bind to the HER2 receptor proteins present on the cell membranes of the submitted tissue sample. Once these antibodies bind to their target antigens, a secondary detection system and a chromogen (typically diaminobenzidine, which produces a brown precipitate) are applied. This chemical reaction allows the pathologist to visualize the localization and intensity of the HER2 protein expression under a light microscope. The diagnostic value of this test is immense, as it directly influences the therapeutic strategy. Patients whose tumors demonstrate high levels of HER2 protein expression (classified as HER2-positive) are candidates for highly effective, targeted anti-HER2 therapies such as trastuzumab, pertuzumab, and antibody-drug conjugates like trastuzumab deruxtecan. Conversely, patients with HER2-negative tumors are spared the potential toxicities and financial burdens of these specific drugs, allowing oncologists to focus on other systemic treatment regimens.

Clinical Procedure: What to Expect

Patient Preparation

Because the HER 2 NEO Immunohistochemistry test is performed on tissue samples that have already been extracted during a surgical biopsy or resection, there is no direct physical preparation required of the patient on the day of the laboratory analysis. However, ensuring the integrity of the specimen prior to testing is of paramount importance. Patients and referring clinical teams must adhere to the following preparation and submission guidelines:

• Submission of Tissue Blocks: The patient or clinical representative must submit the formalin-fixed, paraffin-embedded (FFPE) tissue block along with the corresponding original histopathology report to Lahore PCR Lab.
• Unstained Slides: If tissue blocks cannot be provided, a minimum of 5 to 8 freshly cut, charged, unstained slides (4-micron thickness) must be submitted, along with one hematoxylin and eosin (H&E) stained slide for reference.
• Fixation Details: It is highly recommended to provide details regarding the cold ischemia time (the time between tissue removal and fixation) and the duration of formalin fixation. Ideally, tissue should be fixed in 10% neutral buffered formalin for a minimum of 6 hours and a maximum of 72 hours, in accordance with ASCO/CAP guidelines, to prevent false-negative or false-positive results.
• Clinical History: Provide a complete clinical history, including the primary site of the tumor (e.g., breast, stomach), previous chemotherapy or hormone therapy, and any prior HER2 testing results.

During the Procedure

The analytical phase of the HER 2 NEO Immunohistochemistry test is conducted entirely within the advanced pathology department of Lahore PCR Lab by trained histotechnologists and consultant pathologists. The procedure follows a rigorous, quality-controlled sequence:

• Sectioning: The paraffin block containing the tumor tissue is mounted on a microtome, and ultra-thin sections of approximately 4 micrometers are cut and mounted on positively charged glass slides to prevent tissue detachment during processing.
• Deparaffinization and Rehydration: The slides are heated and treated with clearing agents like xylene to remove the paraffin wax, followed by graded alcohols to rehydrate the tissue sections.
• Antigen Retrieval: To expose the target HER2 epitopes that may have been masked during formalin fixation, the slides undergo Heat-Induced Epitope Retrieval (HIER) using specialized buffer solutions at controlled high temperatures.
• Antibody Incubation: The tissue sections are incubated with a highly specific primary anti-HER2 antibody. This is followed by the application of a secondary detection system containing an enzyme conjugate.
• Chromogen Visualization: A chromogenic substrate (DAB) is applied, which reacts with the enzyme to produce a visible brown staining on the cell membranes where HER2 proteins are located. The slides are counterstained with hematoxylin to visualize cell nuclei, dehydrated, and coverslipped.
• Microscopic Evaluation: A Consultant Pathologist examines the slides under a high-resolution light microscope, assessing the percentage of tumor cells showing membranous staining and the intensity of the stain to assign a clinical score (0, 1+, 2+, or 3+).

When is a HER 2 NEO Immunohistochemistry Test Performed?

Invasive Breast Cancer Diagnosis

The HER 2 NEO Immunohistochemistry test is standard-of-care for every patient newly diagnosed with invasive breast cancer. It is performed on the initial core needle biopsy specimen to guide neoadjuvant (pre-operative) or adjuvant (post-operative) systemic therapy planning. Knowing the HER2 status early helps oncologists decide whether to incorporate targeted monoclonal antibodies into the treatment regimen, which significantly improves disease-free survival rates in breast cancer patients.

Gastric and Gastroesophageal Junction Adenocarcinoma

Physicians routinely request HER2 testing for patients diagnosed with advanced, recurrent, or metastatic adenocarcinoma of the stomach or gastroesophageal junction. Because HER2 overexpression occurs in approximately 10% to 20% of these gastric malignancies, identifying HER2-positive status allows for the addition of trastuzumab to first-line chemotherapy, which has been clinically proven to prolong overall survival in these patients.

Recurrent or Metastatic Cancer Evaluation

In cases where breast or gastric cancer recurs or spreads to distant organs (such as the liver, lungs, or bones), a biopsy of the metastatic lesion is often performed, and HER2 IHC is repeated. This is because the HER2 status of a tumor can change over time or differ between the primary tumor and metastatic sites—a phenomenon known as receptor discordance. Re-evaluating HER2 status ensures that treatment remains aligned with the tumor’s current biological profile.

Determination of Targeted Therapy Eligibility

The primary clinical indication for ordering a HER 2 NEO Immunohistochemistry test is to establish eligibility for anti-HER2 targeted therapies. These highly specific drugs specifically target cells overexpressing the HER2 receptor, blocking downstream signaling pathways that promote cell survival. Without a documented positive IHC score (3+) or an equivocal score (2+) confirmed by molecular testing, patients cannot safely or effectively receive these potent therapeutic agents.

Prognostic Assessment of Tumors

Beyond predicting treatment response, HER2 status serves as an important prognostic indicator. Historically, HER2-positive breast and gastric cancers were associated with a more aggressive clinical course, higher rates of recurrence, and poorer overall survival compared to HER2-negative tumors. While modern targeted therapies have dramatically improved these outcomes, the baseline HER2 status remains a vital piece of prognostic data that helps clinicians understand the biology of the patient’s disease.

What Does a HER 2 NEO Immunohistochemistry Test Detect?

The HER 2 NEO Immunohistochemistry test evaluates several specific cellular and pathological parameters under microscopic examination. The pathologist assesses the following aspects to determine the final score:

• Presence of Membranous Staining: The test specifically detects the localization of the brown chromogen on the cell membrane of invasive tumor cells.
• Completeness of Membrane Staining: Pathologists evaluate whether the staining forms a continuous, unbroken ring around the entire circumference of the cell membrane (typical of breast cancer) or if it is incomplete/basolateral (common in gastric cancer).
• Intensity of Staining: The darkness and visibility of the membranous stain are graded as faint, weak, moderate, or strong.
• Percentage of Stained Tumor Cells: The proportion of viable, invasive cancer cells showing membranous reactivity is calculated (e.g., greater or less than 10%).
• Absence of Staining: The test identifies cells with no visible membranous reactivity, indicating normal or low levels of HER2 protein.
• Internal Positive Controls: The pathologist looks for normal tissue elements within the sample (such as normal breast ducts) which typically show negative or very weak staining, ensuring the run is valid.
• External Controls: Known HER2-positive and HER2-negative tissue samples processed alongside the patient’s slide are evaluated to verify assay accuracy.
• Non-Specific Cytoplasmic Staining: The test distinguishes between true membranous staining and artifactual cytoplasmic staining, which does not count toward a positive score.
• Tumor Heterogeneity: The test detects variations in staining intensity across different areas of the same tumor specimen.
• Artifactual Edge Staining: Pathologists identify and discount intense staining that occurs only at the edges of the tissue section due to drying artifacts.
• Invasive vs. In Situ Components: The test specifically evaluates only the invasive component of the carcinoma, ignoring ductal carcinoma in situ (DCIS) areas.
• Crush Artifacts: Areas of tissue damaged during biopsy collection are identified and excluded from analysis to avoid false readings.
• Fixation Quality: The overall preservation of cellular morphology is assessed to ensure the tissue was fixed adequately.
• Necrotic Areas: The test identifies and avoids evaluating dead or necrotic tumor cells, which can exhibit non-specific staining.
• Weak Membranous Reactivity: Faint, barely perceptible staining in a portion of the cell membrane is detected and classified appropriately.
• Moderate Complete Membranous Reactivity: Continuous staining of moderate intensity in more than 10% of tumor cells is identified.
• Strong Complete Membranous Reactivity: Intense, dark, continuous ring-like staining in more than 10% of tumor cells is detected.
• Lateral/Basolateral Staining: In gastric specimens, U-shaped or lateral membranous staining is specifically identified and scored according to gastric-specific criteria.
• Background Staining: The level of non-specific background coloration is assessed to ensure it does not interfere with interpretation.
• Suitability for Reflex Testing: The test detects equivocal cases (score 2+) that require further evaluation via Fluorescent In Situ Hybridization (FISH).

Turnaround Time and Report Access at Lahore PCR Lab

At Lahore PCR Lab, we understand that waiting for oncology diagnostic results can be an anxious time for patients and their families. The turnaround time for a HER 2 NEO Immunohistochemistry test is typically 3 to 5 working days from the time the tissue block or slides are successfully received and registered at our facility. This timeframe allows our specialized histopathology department to perform precise tissue processing, staining, quality control checks, and a comprehensive review by our consultant pathologists.

Once the diagnostic report is finalized and signed off, patients and their referring physicians are immediately notified via SMS. Reports can be accessed and downloaded securely online through the official Lahore PCR Lab patient portal. Physical copies of the report, along with the returned tissue blocks and slides, can also be collected directly from our main diagnostic center in Lahore.

HER 2 NEO Findings Overview

The interpretation of the HER 2 NEO Immunohistochemistry test follows strict international guidelines established by the American Society of Clinical Oncology (ASCO) and the College of American Pathologists (CAP). The table below outlines the standard scoring parameters and their clinical interpretations:

Structure / Parameter Evaluated	Normal / Negative Findings	Possible Abnormal / Positive Findings
HER2 Protein Expression Score	Score 0 or Score 1+ (Negative; no overexpression of the HER2 protein).	Score 3+ (Positive; high-level overexpression) or Score 2+ (Equivocal; borderline expression).
Membranous Staining Pattern (Breast)	No staining, or faint/barely perceptible incomplete membranous staining in <10% of tumor cells.	Strong, intense, complete circumferential membranous staining in >10% of invasive tumor cells.
Membranous Staining Pattern (Gastric)	No reactivity, or faint membranous reactivity in <10% of tumor cells (biopsy) or tumor cell clusters.	Intense complete, basolateral, or lateral membranous reactivity in >10% of cells (resection) or any cluster (biopsy).
Clinical Interpretation	HER2-Negative tumor; patient is highly unlikely to benefit from HER2-targeted therapies.	HER2-Positive tumor; patient is an ideal candidate for targeted anti-HER2 monoclonal antibody therapy.
Reflex Testing Requirement	No further testing required for standard therapeutic decision-making.	Required for Score 2+ (Equivocal) cases using In Situ Hybridization (FISH/CISH) to detect gene amplification.
Tumor Cell Proliferation Drive	Cell growth is driven by other pathways (e.g., hormone receptors or alternative oncogenic pathways).	Uncontrolled cell division driven directly by overactive HER2 receptor tyrosine kinase signaling.
Therapeutic Actionability	Standard chemotherapy, endocrine therapy, or immunotherapy is considered based on other markers.	Indicates eligibility for targeted drugs like Trastuzumab, Pertuzumab, or Trastuzumab Deruxtecan.

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Lahore PCR Lab for HER 2 NEO Immunohistochemistry?

• Experienced Healthcare Professionals: Our pathology team consists of highly qualified consultant pathologists and histotechnologists with extensive experience in oncological diagnostics.
• Patient-Focused Care: We prioritize patient well-being, ensuring compassionate support, clear instructions, and smooth coordination throughout the testing process.
• Quality Diagnostic Services: Lahore PCR Lab adheres to stringent internal and external quality control protocols to ensure the highest accuracy in immunohistochemistry staining.
• Professional Reporting: Our diagnostic reports are detailed, structured, and compliant with international ASCO/CAP reporting standards, providing clear guidance for oncologists.
• Modern Diagnostic Approach: We utilize advanced staining platforms and high-grade antibodies to minimize background staining and deliver highly reproducible results.
• Comfortable Environment: Our sample collection centers are designed to provide a clean, professional, and stress-free experience for patients submitting specimens.
• Convenient Location: Situated accessibly in Lahore, our main laboratory and collection points make it easy for patients across the region to submit blocks and collect reports.
• Commitment to Accurate Diagnosis: We understand the critical nature of cancer diagnostics and are dedicated to providing precise results that form the foundation of effective treatment.